Navigation Links
Sorbent Therapeutics Presents CLP1001 Phase 2a Study Results at the 16th Annual Meeting of the Heart Failure Society of America
Date:9/10/2012

SUNNYVALE, Calif. and SEATTLE, Sept. 10, 2012 /PRNewswire/ -- Sorbent Therapeutics, Inc. a biopharmaceutical company developing therapies for cardiovascular and renal diseases, today presented positive data from its randomized, double-blind Phase 2a clinical study of CLP1001.  In the study of 111 heart failure patients with chronic kidney disease, CLP1001 demonstrated improvement in heart failure symptoms as compared to placebo.   

Data from the Phase 2a study were presented by Barry M. Massie, M.D., Professor, University of California, San Francisco, President of the Heart Failure Society of America and member of Sorbent's Medical Advisory Board, during the Late-Breaking News Symposium at the Heart Failure Society of America 16th Annual Scientific Meeting in Seattle, Washington.  

"The results of this clinical study suggest that CLP1001 may provide important benefits in addressing the signs and symptoms of heart failure," said Dr. Massie.  "Specifically, the reduction of dyspnea and improved physical functionality among patients dosed with CLP1001 are associated with a better quality of life in heart failure patients already on standard guideline recommended medications."

"Heart failure symptoms are generally debilitating – in spite of currently available therapies.  The positive findings from our Phase 2a clinical trial indicate that CLP1001 may improve patient outcomes," said Howard C. Dittrich, M.D., F.A.C.C., Sorbent's Chief Medical Officer.  "We look forward to working closely with the clinical community on additional clinical studies where we plan to measure the effects of CLP10001 on the physical functionality and overall quality of life of heart failure patients when administered in combination with standard medications for heart failure."

About the Phase 2a Study and Reported Clinical Results

The double-blind, randomized, parallel, placebo-controlled study examined the effe
'/>"/>

SOURCE Sorbent Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorbent Therapeutics CLP1001 Improves Heart Failure Symptoms In Phase 2 Clinical Study
2. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
3. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
4. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
5. Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
6. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
7. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
8. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
9. Global Markets for Animal Therapeutics and Diagnostics
10. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
11. Prime Therapeutics named exclusive pharmacy benefit manager for HR Policy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...  Cyberonics, Inc. (NASDAQ: CYBX ) today announced ... Quarterly highlights 1   Operating results for ... quarter of fiscal 2014, and other achievements, include: , ... 6.8%; , Strong international net sales of $13.2 million, ... , U.S. net product sales reached a new high of ...
(Date:8/20/2014)... 2014 Northstar Global Business Services, Inc., ... of hard work from many talented specialists, the ... and package design.  The new formulation for Snorenz ... the product due to overwhelming evidence of increased ... Nighttime will also include these vitamins, as well ...
(Date:8/20/2014)... Md. , Aug. 20, 2014  The ... lauded the latest results achieved by the real-time, ... as the National Precursor Log Exchange (NPLEx), automatically ... officials track down methamphetamine offenders and make arrests. ... Missouri blocked the sale ...
Breaking Medicine Technology:Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... Sept. 27 Omnicell, Inc ., (Nasdaq: ... systems to acute healthcare facilities, today announced Deaconess ... automated medication dispensing systems and SecureVault™ controlled ... of the medication management process across the health system ...
... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced ... presenting at the JMP Securities Healthcare Conference, being held at ... Bentsur,s presentation is scheduled to take place tomorrow, Tuesday, September ... webcast of Mr. Bentsur,s presentation will be accessible from the ...
Cached Medicine Technology:Deaconess Health System Selects Omnicell's Medication Management System for Product Reliability and Improved Patient Care 2Deaconess Health System Selects Omnicell's Medication Management System for Product Reliability and Improved Patient Care 3Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference 2
(Date:8/21/2014)... (PRWEB) August 21, 2014 Recently, ... among their patients. Alternative medicine is on the ... to millenials. According to The Fiscal Times, young ... treatments over conventional medicine. , The Fiscal Times ... many millenials are embracing alternative medicine. The article ...
(Date:8/21/2014)... with advanced laryngeal cancer appear to have better ... nonsurgical chemoradiation. , Author: Uchechukwu C. Megwalu, M.D., ... Mount Sinai, New York, and colleagues. , Background: ... are diagnosed each year and squamous cell carcinoma ... Prior to 1991, total surgical removal of the ...
(Date:8/21/2014)... NC -- Researchers have pinpointed the environmental source of ... Southern California for decades. It literally grows on trees. ... of a 13-year-old girl, who spent the summer gathering ... hardest hit by infections of the fungus named ... Cryptococcus , which encompasses a number of species including ...
(Date:8/21/2014)... (HealthDay News) -- Not only is eating better and exercising ... of health-care dollars a year, a new study finds. ... health sciences at Wake Forest Baptist Medical Center in Winston-Salem, ... 2 diabetes patients. Participants ranged in age ... an intensive "lifestyle change program" focused on diet and exercise, ...
(Date:8/21/2014)... The W. Montague Cobb/ NMA ... national voice in the elimination of health disparities, ... the 112th National Medical Association’s (NMA) Annual Convention ... John Ruffin, Ph.D, former Director of the National ... life-long career and innovations have had a significant ...
Breaking Medicine News(10 mins):Health News:Van Uden Center Sees Growth in Alternative Medicine 2Health News:Surgery associated with better survival for patients with advanced laryngeal cancer 2Health News:Fungus deadly to AIDS patients found to grow on trees 2Health News:Getting Healthier a Big Money-Saver for People With Diabetes 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2
... by over 11 million children and adults each year, sending ... of anxiety for parents. Findings from a new study published ... ease their concerns however. According to the American Camp ... of injury rates in a large sample of resident camps ...
... from high-flow oxygen treatment , TUESDAY, Dec. 8 ... effective treatment for cluster headaches, British researchers have found. ... as eight per day in bouts that last for ... the drug sumatriptan, but frequent use of the drug ...
... Findings with Newly Returning Veterans , NASHVILLE, Tenn., Dec. ... Iraqi Freedom (OIF) frequently experience high rates of PTSD along ... known about why these symptoms occur together or the most ... One approach that may yield new insights is to search ...
... , NEW YORK, Dec. 8 ... in its catalogue: , http://www.reportli n ... women,s health devices was valued at over $234 million. Over ... accounted for by OB/GYN ultrasound imaging alone. The market for ...
... Va. Any parent knows that sometimes maintaining your cool with ... we get frustrated or angry and lash out at someone ... Tech and two other universities suggests that parents with poorer ... control their emotions with their children. "Angry, oppositional behavior ...
... , NEW YORK, Dec. 8 ... available in its catalogue: , Mesenchymal Stem ... , Mesenchymal stem cells (MSCs) are multipotent stem ... types, including osteoblasts, chondrocytes, myocytes, adipocytes, beta-pancreatic islets cells, ...
Cached Medicine News:Health News:New study finds low rate of injuries at overnight summer camp 2Health News:Oxygen Therapy May Relieve Cluster Headache Pain 2Health News:Researchers Use New Techniques to Assess PTSD 2Health News:Reportlinker Adds Japanese Market for Women's Health Devices 2009 2Health News:Reportlinker Adds Japanese Market for Women's Health Devices 2009 3Health News:Reportlinker Adds Japanese Market for Women's Health Devices 2009 4Health News:Reportlinker Adds Japanese Market for Women's Health Devices 2009 5Health News:Reportlinker Adds Japanese Market for Women's Health Devices 2009 6Health News:Reportlinker Adds Japanese Market for Women's Health Devices 2009 7Health News:Reportlinker Adds Japanese Market for Women's Health Devices 2009 8Health News:Reportlinker Adds Japanese Market for Women's Health Devices 2009 9Health News:Reportlinker Adds Japanese Market for Women's Health Devices 2009 10Health News:Reportlinker Adds Japanese Market for Women's Health Devices 2009 11Health News:Reportlinker Adds Japanese Market for Women's Health Devices 2009 12Health News:Reportlinker Adds Mesenchymal Stem Cells, Advances & Applications 2Health News:Reportlinker Adds Mesenchymal Stem Cells, Advances & Applications 3Health News:Reportlinker Adds Mesenchymal Stem Cells, Advances & Applications 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: